AIMS: Unprotected left main (ULM) @entity453 is encountered in 3%-10% of coronary angiograms and is associated with high mortality. The survival of @entity1 with ULM disease presenting with @entity1187 ( @entity1187 ) depends on different variables and is lowest in those with @entity1455 ( @entity1455 ). The aim of the present study was to estimate the impact of baseline characteristics on the subsequent clinical outcome in @entity1 treated by percutaneous coronary intervention (PCI) of ULM for @entity1187 . METHODS AND RESULTS: One hundred and thirty-four @entity1 were retrieved from our database and followed by phone or physician visit. @entity1 were classified into two groups according to their presentation ( @entity1455 /STEMI group: @entity1 presenting with @entity1455 or ST-elevation @entity583 ; NSTEMI/UA group: @entity1 with @entity3257 or @entity1459 ). Data collected were baseline characteristics, procedural information, and clinical outcome. The primary endpoint was all-cause mortality at 6-month follow-up. The secondary end point was a composite of @entity204 , @entity583 , and any repeat revascularisation, i.e., major adverse @entity299 (MACE). Kaplan-Meier curves were computed for survival. Logistic regression determined that hypercholesterolaemia (OR 6.22, p=0.03), high pre-procedural TIMI score (OR 3.89, p=0.01), preserved left ventricular ejection fraction (OR 1.07, p=0.01) and LM as culprit lesion (OR 8.57, p=0.01) protected against development of @entity1455 . Primary outcome occurred in 44% of @entity1 in the @entity1455 /STEMI group compared to 6% in the NSTEMI/UA group (p<0.001). MACE were observed in 30 @entity1 (48%) of the @entity1455 /STEMI group and in 12 @entity1 (19%) of the NSTEMI/UA group (p=0.001). CONCLUSIONS: Acute @entity301 due to @entity850 is associated with high mortality even after successful PCI. @entity1 presenting with @entity1455 or STEMI are at particular risk.

Clinical outcomes after PCI for @entity1187 in unprotected left main XXXX : insights from the Swiss Acute Left Main Coronary Vessel Percutaneous Management (SALVage) study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndromes'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary syndrome'] @entity1459 :: ('MESH:D000789', 'Disease') :: ['unstable angina'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease'] @entity850 :: ('MESH:D003251', 'Disease') :: ['critical ULM stenosis'] @entity1455 :: ('MESH:D012770', 'Disease') :: ['CS', 'cardiogenic shock'] @entity204 :: ('MESH:D003643', 'Disease') :: ['cardiac death'] @entity3257 :: ('MESH:C580335', 'Disease') :: ['non-STEMI']
@entity453 :: (MESH:D003324,Disease) :: ['coronary artery disease']
